Early Cost-effectiveness Analysis of Risk-Based Selection Strategies for Adjuvant Treatment in Stage II Colon Cancer: The Potential Value of Prognostic Molecular Markers

Added 88 days ago (02.09.2021)
Authors: Jongeneel, G., Greuter, M. J. E., Kunst, N., van Erning, F. N., Koopman, M., Medema, J. P., Vermeulen, L., Ijzermans, J. N. M., Vink, G. R., Punt, C. J. A., Coupe, V. M. H.
Read article